Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals. - Wikidata - awgldk - TriplyDB

Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals.

Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals.

http://www.wikidata.org/entity/Q34195386

about

Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa Association of low level viremia with inflammation and mortality in HIV-infected adults DermaVir: a plasmid DNA-based nanomedicine therapeutic vaccine for the treatment of HIV/AIDS.A Robust PCR Protocol for HIV Drug Resistance Testing on Low-Level Viremia Samples.Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients Coagulation and morbidity in treated HIV infection.Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients.Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion.Residual immune dysregulation syndrome in treated HIV infection.BET bromodomain inhibition as a novel strategy for reactivation of HIV-1 A flavonoid, luteolin, cripples HIV-1 by abrogation of tat function.Incomplete adherence to antiretroviral therapy is associated with higher levels of residual HIV-1 viremia.Association of residual plasma viremia and intima-media thickness in antiretroviral-treated patients with controlled human immunodeficiency virus infection Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.Inguinal lymph node and anorectal mucosal biopsies for human immunodeficiency virus research protocols in an emerging nation: patient outcomes and lessons learned Baseline cellular HIV DNA load predicts HIV DNA decline and residual HIV plasma levels during effective antiretroviral therapy.Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation Quantification of viral loads lower than 50 copies per milliliter by use of the Cobas AmpliPrep/Cobas TaqMan HIV-1 test, version 2.0, can predict the likelihood of subsequent virological rebound to >50 copies per milliliter.Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells.Modelling HIV-1 2-LTR dynamics following raltegravir intensification.Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but Does Not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy Negative Feedback Regulation of HIV-1 by Gene Editing Strategy.HIV-associated disruption of mucosal epithelium facilitates paracellular penetration by human papillomavirus Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.Altered Monocyte and Endothelial Cell Adhesion Molecule Expression Is Linked to Vascular Inflammation in Human Immunodeficiency Virus Infection HIV, Tat and dopamine transmission.Bimodal distribution of Trypanosoma cruzi antibody levels in blood donors from a highly endemic area of Argentina: what is the significance of low-reactive samples?Reduced adherence to antiretroviral therapy is associated with residual low-level viremia.Genetic defects in the nef gene are associated with Korean Red Ginseng intake: monitoring of nef sequence polymorphisms over 20 years.Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells.Combining Cell and Gene Therapy in an Effort to Eradicate HIV.Immune activation despite suppressive highly active antiretroviral therapy is associated with higher risk of viral blips in HIV-1-infected individuals.Human immunodeficiency virus and hepatitis C virus coinfection in Nepal.HIV as a Cause of Immune Activation and Immunosenescence.Examining Relationships between Metabolism and Persistent Inflammation in HIV Patients on Antiretroviral Therapy

P2860

Q27024262-53DFF5C6-589E-4CC3-9671-302A7DBBC0AC Q28477379-49C211CF-E56C-4BE1-8BA4-34C1A9435FC4 Q28743237-9595D10C-BC06-4E5C-B1B1-FD0E06CCD1D4 Q30408029-49C44136-A183-47B4-87DB-73BFE4F36565 Q33572108-3771113A-4B7B-4037-8582-0833B1373047 Q33575261-4FC93D64-4F5C-4EE3-8282-7B8C4C5F9FF2 Q33614424-50A7B057-CE35-4AC1-80C8-987E5900E2CF Q33798584-5AE50809-7D80-4B63-A958-3A57393E493A Q33987485-9F31BC96-FC60-450E-A544-E5FF29022461 Q34020121-A5DE30FE-824F-48B5-BCC0-B6074C925715 Q34032827-E8608B7C-A6BE-42C5-BF0E-C8266BB5D4A1 Q34091121-622E2B00-531A-456B-BCB0-D9CDE952BC3A Q34324005-1169D008-80FA-4899-86E0-EBDF4DFD1CD1 Q34557631-C6D8A186-F893-4CB0-9B1A-5FB23C092E0F Q34598155-9CCEEFE8-AFF3-4C1C-B37E-6CC21AA63AC8 Q35188710-C4F88B9A-33FA-426C-B084-2639056E78D8 Q35689000-6754E765-2832-42ED-B813-C204AE56893D Q36495526-8E1C3CFD-CA6D-4511-8016-4A786302E85C Q36796554-371F749B-C596-45BB-BA55-D9630CF14C86 Q36826684-CD9F4141-2919-4E3E-B731-1E5442697521 Q36882465-F3B115DB-E588-4BB9-A12B-E46CA83C2E9E Q36904249-7E23EA81-1F74-4355-A644-FAE17D9E2C63 Q37149855-E831124F-78FC-47F3-8560-409DC494AAA6 Q37177251-8BCC9D30-51F6-48BD-9E9C-E50407B3B077 Q37257571-296608C7-2A36-449F-A4C2-DAAA3D1FD484 Q37308125-71F3B16C-E592-45BA-B2AB-64D0590C929C Q37543675-9F085416-2CCE-415F-B1B0-81C66981B8BB Q38812005-DCCAC58B-D0B2-4A85-BF54-A4BAD2122DF5 Q39392248-94B3628F-E7AE-4D6D-B457-E7126037BC2A Q40164081-94EBF8F9-6C7A-4BEE-A622-86B47134409B Q40240807-FEFA8EFB-20F9-4D20-8E1A-62BA753D79D0 Q40351372-B897CEAD-33C1-42E8-BA04-33778E4BA5E4 Q40427938-1D90937E-FE1E-4D7D-8E4F-042D8F93E8BC Q42226567-17A6BE92-C0FA-4778-9550-E24FA7C3ED87 Q42265849-E5806C6E-BAF5-4036-A244-FFAC366158A2 Q47151081-8C5D239F-815B-4BC3-938A-A6AF71C3D49B Q58549748-CE152504-F9B5-4C07-B59B-E2BACB19416B

P2860

Evidence of persistent low-level viremia in long-term HAART-suppressed, HIV-infected individuals.

http://www.wikidata.org/entity/Q34195386

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@ast

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@en

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@nl

type

label

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@ast

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@en

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@nl

prefLabel

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@ast

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@en

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@nl

P1433

Q34195386-29B7E940-B6D2-4260-A3E5-B60481237890

P1476

Q34195386-F08D66FB-EE11-41F8-B2EE-B28E1FD3CE00

P2093

Q34195386-038C098E-8FDF-42E3-AC5A-A5E0EE83B96F

Q34195386-289E0FF0-6D5C-4151-B4C1-F51DF0093E00

Q34195386-4B3A973E-130A-4F4A-AE9D-A7E459D58E5B

Q34195386-55EB40CE-44FE-4E0C-B313-056A2380BEBE

Q34195386-613C9F44-2422-48BD-9D0E-E5CCB6ECE8E6

Q34195386-A4D258CA-4C9A-4CF6-BBE9-CB905B52D4FD

Q34195386-B86FE1DC-698D-4B16-A063-67EA11A0F059

Q34195386-CF0B32E1-5935-440F-831A-A1D47794B613

P2860

Q34195386-1F4FB2E3-B954-4B1E-A5A2-16D998579735

Q34195386-284B4BE8-FB7B-4490-8FA7-14FE4315C873

Q34195386-2A4DF25F-B78A-4C04-B9B5-DC8F6EDF072A

Q34195386-3E79F821-31AA-4235-BA91-1946A7723CB5

Q34195386-413AFE8C-0912-4D50-BECE-677462139A21

Q34195386-41428ABE-D4BA-4A11-B236-70FFF3D21715

Q34195386-646F4DA1-FB4D-4A2D-B8B3-719C6BF2F43A

Q34195386-70B2654B-DB1C-48FD-8623-9D5557E905ED

Q34195386-7BBD8658-4DA3-4F22-A0AB-5FC429D12CCD

Q34195386-A39768C2-576D-4768-B929-26C76397AB7A

P304

Q34195386-82B4EE0B-14FD-4BE8-BEF8-6A451D486D8C

P31

Q34195386-38945280-0591-4EDE-80EF-2E87641AA93A

P356

Q34195386-EF4743C3-5ED9-4D6A-8920-002D395C2771

P407

Q34195386-7A983C31-7645-489D-BE00-3C04521896CF

P433

Q34195386-38B8E0C6-C2D7-4358-BCA3-048089FD22C6

P478

Q34195386-AE34668C-6A82-4EEF-A375-844D92854F53

P50

Q34195386-2134F315-F8C8-46BD-98F4-9FC64F696A9A

Q34195386-81535427-6686-44EF-935F-27DC0130ABC3

Q34195386-D25EF9F2-5469-454E-8E8E-AECB34EAB14C

Q34195386-E3756A56-4D2C-4AB3-B82C-8AF27FBC6671

P577

Q34195386-7097A1ED-77F6-4791-9C13-B67088B97137

P5875

Q34195386-C2F81D90-65B4-4281-A8C1-AB4AFB526C34

P698

Q34195386-254E81B7-7DEF-4C63-BC49-6B73B8FB80D6

P932

Q34195386-95CC03C9-D608-45AD-B0BB-31F9C2513378

P356

QAD.0B013E32833DBA03

P1433

P1476

Evidence of persistent low-lev ...... sed, HIV-infected individuals.

@en

P2093

Colleen F Kelley

http://www.w3.org/2001/XMLSchema#string

Hiroyu Hatano

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Linnen

http://www.w3.org/2001/XMLSchema#string

Jeffrey N Martin

http://www.w3.org/2001/XMLSchema#string

Peter W Hunt

http://www.w3.org/2001/XMLSchema#string

Philip J Norris

http://www.w3.org/2001/XMLSchema#string

Rebecca Hoh

http://www.w3.org/2001/XMLSchema#string

Torsten B Neilands

http://www.w3.org/2001/XMLSchema#string

P2860

Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

Inflammatory and coagulation biomarkers and mortality in patients with HIV infection

CD4+ count-guided interruption of antiretroviral treatment

HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy.

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy.

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy.

Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years.

Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing.

P304

2535-2539

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/QAD.0B013E32833DBA03

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

Michael P. Busch

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45282549

http://www.w3.org/2001/XMLSchema#string

P698

20651585

http://www.w3.org/2001/XMLSchema#string

P932

2954261

http://www.w3.org/2001/XMLSchema#string